Acute Coronary Syndrome - Drug Pipeline Landscape, 2023

Acute coronary syndrome is a term for a group of conditions that suddenly stop or severely reduce blood from flowing to the heart muscle. When blood cannot flow to the heart muscle, the heart muscle can become damaged. Acute coronary syndrome causes no cell death, the reduced blood flow changes how the heart works and is a sign of a high risk of heart attack.

To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31165

Acute coronary syndrome usually results from the buildup of fatty deposits (plaques) in and on the walls of coronary arteries, the blood vessels delivering oxygen and nutrients to heart muscles. Plaque can tear suddenly, and a blood clot forms around it, severely narrowing or blocking the artery.

Signs and symptoms of acute coronary syndrome includes chest pain (angina) or discomfort, shortness of breath, sudden, heavy sweating, Feeling restless or apprehensive, fast, or irregular heartbeat. Doctors most often diagnose acute coronary syndrome by using tests like electrocardiogram (ECG), A troponin blood test can show if the cells in the heart have been damaged, echocardiogram, coronary angiography, exercise stress test, nuclear stress test, stress echocardiography.

Read more about Acute Coronary Syndrome - Drug Pipeline here: https://www.globalinsightservices.com/reports/acute-coronary-syndrome-drug-pipeline-landscape

Report Highlights
Global Insight Service's, Acute Coronary Syndrome - Drug Pipeline Landscape, 2023 report provides an overview of the Acute Coronary Syndrome pipeline drugs. This report covers detailed insights on Acute Coronary Syndrome drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Acute Coronary Syndrome pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS31165

Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Acute Coronary Syndrome treatment such as BAT2094, Dalcetrapib, Evolocumab and others. Key players involved in the development of therapies to treat acute coronary syndrome are Amgen, AstraZeneca, Bio-Thera Solutions Ltd, CSL Behring, DalCor Pharmaceuticals and others. One drug is under Pre-Registration and four drugs are in late-stage Phase III clinical trials and one drug is in Phase II clinical trials and some other drugs are under Phase I stage of development.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31165

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.